Back to Lung Cancer
NCT00003317
NCT00003317
Who may be able to join
Who might be able to join this trial:
- You are 18 years of age or older
- You have been diagnosed with stage IIIA non-small cell lung cancer, confirmed by a tissue sample (biopsy)
- Your cancer was fully removed through lung surgery (such as removal of one lobe, two lobes, the whole lung, or a sleeve procedure), performed through any surgical approach including keyhole/camera-assisted surgery
- There is no known cancer remaining in your body after surgery
- The cancer was found to have spread to lymph nodes in the chest only when discovered during surgery or confirmed after surgery by lab analysis of removed tissue
- All visibly affected lymph nodes were removed during surgery
- If a scan showed enlarged lymph nodes (larger than 1.5 cm), a procedure to check those nodes (called a mediastinoscopy) was done and did not show cancer before surgery (confirm with trial site)
- Your blood cell counts meet certain minimum levels — your white blood cells (granulocytes) and platelets are within an acceptable range
- Your liver function tests (bilirubin and SGOT) and kidney function are within acceptable ranges
- You are not pregnant or breastfeeding
Who may not be able to join:
- You have any known cancer still remaining after surgery
- Cancer in your chest lymph nodes was known or confirmed before surgery (e.g., through a pre-surgical mediastinoscopy)
- You have had chemotherapy before for this type of lung cancer
- You have had radiation therapy before for this type of lung cancer
- You are currently receiving or planning to receive other chemotherapy, hormone therapy (with limited exceptions such as steroids for adrenal problems, or anti-nausea medication), or growth factor treatments alongside this trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 3
Sponsor
Alliance for Clinical Trials in Oncology
Registry
clinicaltrials_gov
Start date
1 May 1998
Est. completion
1 June 2005
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
Overall survival; Disease-free survival; Patterns of local and distant recurrence in these patients; Toxicities associated with chemotherapy with or without adjuvant radiotherapy in patients.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.